Q2 2026 13F · SEC CIK 1826434
Tri Locum Partners LP
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $813.2M
- Reported positions
- 19
- Top holdings a year, 3 yrs
- +32.3%
- Assets under management
- $1.1B
Tri Locum Partners LP is a hedge fund that reported 19 positions worth $813.2M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Johnson & Johnson (JNJ, 13.3%), Vertex Pharmaceuticals Inc (VRTX, 12.3%), Eli Lilly & Co (LLY, 11.3%). A portfolio copying its top holdings returned 32.3% a year over the last 3 years, against 20.4% for the S&P 500.
Tri Locum Partners LP holdings all 19 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| JNJJohnson & Johnson | 13.3% | +2.5% | $107.9M |
| VRTXVertex Pharmaceuticals Inc | 12.3% | +56.0% | $100.2M |
| LLYEli Lilly & Co | 11.3% | +23.8% | $91.8M |
| ASNDAscendis Pharma A/s | 8.5% | — | $69.0M |
| DXCMDexcom Inc | 6.8% | +17.5% | $55.3M |
| AXSMAxsome Therapeutics, Inc. | 6.6% | +253.1% | $53.7M |
| JAZZJazz Pharmaceuticals PLC | 6.6% | +39.7% | $53.4M |
| ELVNEnliven Therapeutics Inc | 5.4% | — | $44.0M |
| ARGNFArgenx SE | 4.7% | +31.5% | $38.6M |
| MDGLMadrigal Pharmaceuticals Inc | 4.5% | -33.9% | $36.7M |
| RVMDRevolution Medicines Inc | 3.5% | — | $28.4M |
| UTHRUnited Therapeutics Corp Del | 3.1% | -33.2% | $25.5M |
| TEVATeva Pharmaceutical Inds Ltd | 3.1% | -26.9% | $25.3M |
| TARSTarsus Pharmaceuticals Inc | 2.5% | +30.0% | $20.7M |
| ISRGIntuitive Surgical Inc | 2.3% | -68.7% | $19.1M |
| CYTKCytokinetics | 2.0% | — | $16.5M |
| DNTHDianthus Therapeutics Inc | 1.4% | -17.1% | $11.8M |
| BBNXBeta Bionics Inc | 1.0% | — | $7.7M |
| 24477V105Definium Therapeutics Inc | 0.9% | -55.9% | $7.7M |
What Tri Locum Partners LP bought and sold in Q2 2026, against Q1 2026.
New positions
- ASND Ascendis Pharma A/s8.5% of 13F
- ELVN Enliven Therapeutics Inc5.4% of 13F
- RVMD Revolution Medicines Inc3.5% of 13F
- CYTK Cytokinetics2.0% of 13F
- BBNX Beta Bionics Inc1.0% of 13F
Added to
- AXSM Axsome Therapeutics, Inc.+253.1% shares
- VRTX Vertex Pharmaceuticals Inc+56.0% shares
- JAZZ Jazz Pharmaceuticals PLC+39.7% shares
- ARGNF Argenx SE+31.5% shares
- TARS Tarsus Pharmaceuticals Inc+30.0% shares
- LLY Eli Lilly & Co+23.8% shares
- DXCM Dexcom Inc+17.5% shares
Reduced
- ISRG Intuitive Surgical Inc-68.7% shares
- Definium Therapeutics Inc-55.9% shares
- MDGL Madrigal Pharmaceuticals Inc-33.9% shares
- UTHR United Therapeutics Corp Del-33.2% shares
- TEVA Teva Pharmaceutical Inds Ltd-26.9% shares
- DNTH Dianthus Therapeutics Inc-17.1% shares
Sold out
- TMO Thermo Fisher Scientific Incwas 9.1%
- Ascendis Pharma A/swas 8.2%
- NUVL Nuvalent Incwas 4.4%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +65.0% /yr
- S&P 500 +20.1%
- 3 years
- +32.3% /yr
- S&P 500 +20.4%
- 5 years
- +24.6% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $813.2M | 19 |
| Q1 2026 | $712.5M | 17 |
| Q4 2025 | $770.1M | 15 |
| Q3 2025 | $435.1M | 18 |
| Q2 2025 | $329.5M | 23 |
| Q1 2025 | $194.9M | 22 |
| Q4 2024 | $482.7M | 28 |
| Q3 2024 | $417.4M | 20 |
| Q2 2024 | $395.5M | 25 |
| Q1 2024 | $288.4M | 27 |
| Q4 2023 | $203.7M | 23 |
| Q3 2023 | $311.7M | 60 |
Questions about Tri Locum Partners LP's portfolio
What stocks does Tri Locum Partners LP own?
Tri Locum Partners LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 19 positions worth $813.2M. The largest are Johnson & Johnson (JNJ) at 13.3%, Vertex Pharmaceuticals Inc (VRTX) at 12.3%, Eli Lilly & Co (LLY) at 11.3%, Ascendis Pharma A/s (ASND) at 8.5% and Dexcom Inc (DXCM) at 6.8%.
What did Tri Locum Partners LP buy last quarter?
In Q2 2026, Tri Locum Partners LP added a new position in Ascendis Pharma A/s (ASND), a new position in Enliven Therapeutics Inc (ELVN), a new position in Revolution Medicines Inc (RVMD), a new position in Cytokinetics (CYTK), a new position in Beta Bionics Inc (BBNX), Axsome Therapeutics, Inc. (AXSM) (+253.1% shares), Vertex Pharmaceuticals Inc (VRTX) (+56.0% shares) and Jazz Pharmaceuticals PLC (JAZZ) (+39.7% shares), compared with its Q1 2026 filing.
What did Tri Locum Partners LP sell last quarter?
In Q2 2026, Tri Locum Partners LP sold all of Thermo Fisher Scientific Inc (TMO), sold all of Ascendis Pharma A/s, sold all of Nuvalent Inc (NUVL), Intuitive Surgical Inc (ISRG) (-68.7% shares), Definium Therapeutics Inc (-55.9% shares) and Madrigal Pharmaceuticals Inc (MDGL) (-33.9% shares), compared with its Q1 2026 filing.
How has Tri Locum Partners LP's portfolio performed?
A portfolio copying Tri Locum Partners LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +32.3% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +65.0% against +20.1%. Over 5 years: +24.6% a year against +11.6%.
When is Tri Locum Partners LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Tri Locum Partners LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Tri Locum Partners LP manage?
Tri Locum Partners LP reported $1.1B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $813.2M.